Downloaded from:

Similar documents
I n 1960 Wagner et al reported the first conclusive association

Prediction of mesothelioma and lung cancer in a cohort of asbestos exposed workers

Asbestos-related diseases in Great Britain, 2018

The European mesothelioma epidemic

Predictions of mortality from mesothelial

MESOTHELIOMA MORTALITY IN MEN: TRENDS DURING AND PROJECTIONS FOR IN SPAIN.

First and subsequent asbestos exposures in relation to mesothelioma and lung cancer mortality

International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision

Estimating the Number of Asbestos-related Lung Cancer Deaths in Great Britain from 1980 to 2000

Occupational Characteristics of Cases with Asbestosrelated Diseases in The Netherlands

Lung cancer and mesothelioma in the pleura and peritoneum among Swedish insulation workers

Future trends in mortality of French men from mesothelioma

Asbestos Compliance and Retrospective Risk Analysis

Quantification of the effect of mammographic screening on fatal breast cancers: The Florence Programme

Modelling Diabetes: A multi-state life table model

Malignant Mesothelioma in Australia,

Pleural and peritoneal mesotheliomas in the Friuli Venezia Giulia register: data analysis from 1995 to 2015 in Northeastern Italy

Mortality of workers in a French asbestos cement factory

Downloaded from:

Cohort analysis of cigarette smoking and lung cancer incidence among Norwegian women

British Journal of Industrial Medicine 1985;42:

24 March Mr Peter Tighe Chief Executive Officer Asbestos Safety and Eradication Agency Level 8, 255 Elizabeth Street SYDNEY NSW 2000.

The Hazards of Chrysotile Asbestos: A Critical Review

Extract from Cancer survival in Europe by country and age: results of EUROCARE-5 a population-based study

WINTER SEASON 2016/17 MORTALITY SUMMARY REPORT FROM THE EUROMOMO NETWORK

Cardiovascular disease mortality among British asbestos workers (1971e2005)

IOSH No Time to Lose campaign: working together to tackle asbestos-related cancer #NTTLasbestos. Jonathan Hughes IOSH Vice President

Elimination of Asbestos-Related Diseases WHO activities

Asbestos and cancer: a cohort followed up to death

Mortality from cancer of the lung in Serbia

Trend and distribution of mesothelioma in Denmark M. Andersson' & J.H. Olsen2

Incidence among men of asymptomatic abdominal aortic aneurysms: estimates from 500 screen detected cases

Geography of Mesothelioma: An Overview

Overview of Epidemiological Studies and Trends in Paediatric CT use. Mark S. Pearce, PhD

Human Health Risk Assessment

Tim Driscoll Sydney School of Public Health University of Sydney. Occupational cancer Cancer Council forum May 2012

Review of the effectiveness of predictive models for mesothelioma to identify lessons for asbestos-related policy

Chrysotile possesses relatively long, flexible, and wavy fibers. Amphibole asbestos has fibers that are substantially more brittle than chrysotile.

Report on Cancer Statistics in Alberta. Breast Cancer

Comment on Caerphilly Council s: Cwmcarn High School - your questions answered.

Trends in mortality from leukemia in subsequent age groups

Pleural mesothelioma and lung cancer risks in relation to occupational history and asbestos lung burden

Introduction, Summary, and Conclusions

ferrochromium workers

had been in contact with crocidolite asbestos. By the time of the First International Congress on the

EPIDEMIOLOGICAL STUDY

ASBESTOS. What is asbestos?

COPYRIGHTED MATERIAL. Epidemiology, Risk Factors and Prevention CHAPTER 1. Martin Muers, Ian Hunt and Jesme Fox. Epidemiological trends

HPSC SEXUALLY TRANSMITTED INFECTIONS IN IRELAND, 2011

UK Complete Cancer Prevalence for 2013 Technical report

Keywords Cytology-screening, statistics-epidemiological surveys.

Published in: Medical Journal of Australia. DOI: /mja Document Version Peer reviewed version

Asbestos. What is it? Where is it? What to do when we suspect it

RecentTrends in Prostate Cancer Incidence and Mortality in Southeast England

New guidelines for the management of norovirus outbreaks in acute and community health and social care settings

Malignant pleural mesothelioma: an epidemiological perspective

ASBESTOS - RELATED LUNG CANCER: AN UNRECOGNIZED HEALTH HAZARD L. CHRISTINE OLIVER, MD, MPH, MS OEH SEMINAR SERIES NOVEMBER 23, 2018

Epidemiology of Malignant Mesothelioma An Outline

of dockyard workers A proportional study of cancer registrations 10o K. P. S. LUMLEY Medical Research Unit,

Downloaded from:

CANCER INCIDENCE NEAR THE BROOKHAVEN LANDFILL

C aring for patients with interstitial lung disease is an

WORK RELATED MESOTHELIOMA AND WORKERS COMPENSATION IN WESTERN AUSTRALIA

UK Liver Transplant Audit

Cancer Mortality, Recent Trends And Perspectives

Estimation of the past and future burden of mortality from mesothelioma in France

Cost-effectiveness of brief intervention and referral for smoking cessation

Incidence of cancer among anthophyllite asbestos

2. Morbidity. Incidence

Trends in Hospital Admissions For Diabetes Complications

The accident injuries situation

of Supply, Home Office, and War Office papers an unknown date in the 1930s these respirators were

BD5.3. Report of Elimination of Asbestos- Related Diseases. ICOH Mid-Term Meeting February 8-10, 2014 Helsinki, Finland

B enign pleural disease (discrete plaques and pleural

HIV in the United Kingdom: 2009 Report

Mortality of female gas mask assemblers

WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE

Recent developments in mortality

Investigation of cancer incidence and mortality at a Scottish semiconductor manufacturing facility

Planning an effective HPV vaccination launch: The key indicators for success Joakim Dillner

Research Report. An assessment of risks due to asbestos on farm tracks and rights of way in South Cambridgeshire

Lung Cancer. Background and Developments Regarding the Role of Asbestos as a Cause of Lung Cancer and New Lung Cancer Claims

1.4 - Linear Regression and MS Excel

NEOPLASIA AMONG INSULATION WORKERS IN TIIE UNITED STATES WITH SPECIAL REFERENCE TO INTKA-ABDOMINAL NEOPLASIA

Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)

Breast and Colorectal Cancer mortality. in Scotland can we do better?

Downloaded from:

Information Services Division NHS National Services Scotland

Cancer mortality in a cohort of asbestos textile workers

National Bowel Cancer Audit Supplementary Report 2011

Introduction. Our legislative framework makes it compulsory for an employer to protect the environment from any pollution (water, air and soil).

Rare Urological Cancers Urological Cancers SSCRG

SOME EPIDEMIOLOGICAL ASPECTS OF DOWN'S SYNDROME IN BRITISH COLUMBIA

Changing Patterns of Occupational Respiratory Disease. Malcolm Sim

Report on Cancer Statistics in Alberta. Kidney Cancer

of men employed. Because of this lack of official were in existence for recording the causes of death in

Prof. Dr. Gabor Ternak

ESTIMATES OF THE FRACTION OF SEVERAL CANCERS ATTRIBUTABLE TO OCCUPATIONAL EXPOSURE TO SOME CARCINOGENS IN FRANCE

Epidemiology of tuberculosis in Northern Ireland. Annual surveillance report 2007

Transcription:

Hodgson, JT; McElvenny, DM; Darnton, AJ; Price, MJ; Peto, J (25) The expected burden of mesothelioma mortality in Great Britain from 22 to 25. British journal of cancer, 92 (3). pp. 587-93. ISSN 7-92 DOI: 1.138/sj.bjc.66237 Downloaded from: http://researchonline.lshtm.ac.uk/12944/ DOI: 1.138/sj.bjc.66237 Usage Guidelines Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk. Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/

British Journal of Cancer (25) 92, 587 593 All rights reserved 7 92/5 $3. www.bjcancer.com The expected burden of mesothelioma mortality in Great Britain from 22 to 25 JT Hodgson*,1, DM McElvenny 1, AJ Darnton 1, MJ Price 1 and J Peto 2,3 1 and Medical Statistics Unit, Health and Safety Executive, Magdalen House, Trinity Road, Bootle, Merseyside L2 3QZ, UK; 2 Department of and Population Health, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK; 3 Section, Institute of Cancer Research, 15 Cotswold Road, Belmont, Sutton, Surrey SM2 5NG, UK The British mesothelioma register contains all deaths from 1968 to 21 where mesothelioma was mentioned on the death certificate. These data were used to predict the future burden of mesothelioma mortality in Great Britain. Poisson regression analysis was used to model male mesothelioma deaths from 1968 to 21 as a function of the rise and fall of asbestos exposure during the 2th century, and hence to predict numbers of male deaths in the years 22 25. The annual number of mesothelioma deaths in Great Britain has risen increasingly rapidly from 153 deaths in 1968 to 1848 in 21 and, using our preferred model, is predicted to peak at around 195 to 245 deaths per year between 211 and 215. Following this peak, the number of deaths is expected to decline rapidly. The eventual death rate will depend on the background level and any residual asbestos exposure. Between 1968 and 25, there will have been approximately 9 deaths from mesothelioma in Great Britain, 65 of which will occur after 21. British Journal of Cancer (25) 92, 587 593. doi:1.138/sj.bjc.66237 www.bjcancer.com Published online 25 January 25 Keywords: mesothelioma; mortality; Great Britain; prediction Mesothelioma is a formerly rare cancer that principally affects the pleura and the peritoneum (Greenberg and Lloyd Davies, 1974) and is almost always caused by asbestos exposure. The disease is rapidly fatal, most of those affected dying within a year of diagnosis (Peto et al, 1995). There is a long latent period between first exposure to asbestos and diagnosis of mesothelioma that is seldom less than 15 years and often exceeds 6 years (Bianchi et al, 1997). In all, 85% of deaths are among men, and the risk is highest in occupations with substantial exposure to asbestos (McElvenny et al, 25). Previous predictions of future numbers of mesothelioma deaths in Britain were based on observed male deaths between 1968 and 1991 (Peto et al, 1995; Hodgson et al, 1997) and were derived from a simple birth cohort model in which mesothelioma risk was related independently to age and to date of birth. These analyses suggested that male mesothelioma deaths would peak at about 27 33 deaths around 22. The data have conformed to this model well up to 1991, but from the 199s show a departure from fit for some of the later cohorts (Figure 1A and B). The slower increase with age for mesothelioma death rates in the 199s implies that the simple age cohort model is not reliable. We fitted the age cohort model as confirmation of these observations, but our main models related current mortality to past asbestos exposure levels and did not assume the same age distribution of mortality in different birth cohorts. *Correspondence: Dr JT Hodgson; E-mail: john.hodgson@hse.gsi.gov.uk Received 23 August 24; revised 29 October 24; accepted 3 November 24; published online 25 January 25 MATERIALS AND METHODS The mesothelioma register is described in detail elsewhere (McElvenny et al, 25). Briefly, deaths occurring in England, Scotland and Wales, where mesothelioma was mentioned on the death certificate, are notified annually to the Health and Safety Executive by the Office for National Statistics and the General Register Office for Scotland. Originally, this was done manually as part of the coding of causes of death, but since 1992 (1996 in Scotland), the computerised national mortality database has been scanned. Checks for completeness include searching deaths in England and Wales for alternative spellings of mesothelioma and flagging cancer registrations with a morphology code consistent with mesothelioma for death notification at the National Health Service Central Registers in Edinburgh and Southport. Details of the analysis, which was based on deaths in men aged 2 89 years between 1968 and 21, are given in Appendix A1. The model parameters were estimated iteratively, and the deviance (based on observed and expected numbers aggregated over 5-year groups by age, date of birth and year of death) was used to assess overall goodness of fit. Two of the model parameters, k (the power of time defining the increase in risk after exposure) and H (the half-life for clearance of asbestos from the lung), are closely correlated and cannot be independently estimated. The effect of reducing the half-life is to increase the best-fit value of k, but the fit of the model is affected only slightly. Since fitting the model with both H and k is unstable, we used two versions of the model, one with (effectively) no clearance (H ¼ 1 years) and the other with a clearance half-life of 15 years a value suggested from the modelling of mortality of the Wittenoom workforce (Berry, 1991).

588 A 1 Rate per million B 1 1 1.1 2 3 4 5 6 7 8 9 Age (years) 1 1943 47 1938 42 1933 37 1928 32 1923 27 1918 22 1913 17 198 12 193 7 1898 2 1893 97 1888 92 1883 87 1878 82 Rate per million 1 1 1.1 1978 82 1973 77 1968 72 1963 67 1958 62 1953 57 1948 52 1943 47 1938 42.1 2 3 4 5 6 7 Age (years) Figure 1 (A) Mesothelioma death rates by 5-year cohort and age group for males born 1878 1937 (note: The earlier cohorts are to the lower right of the chart). (B) Mesothelioma death rates by 5-year cohort and age group for males born 1938 1982 (note: The earlier cohorts are to the upper left of the chart). The adequacy of the model was tested by examining deviance residuals and by comparing observed and fitted numbers of mesothelioma deaths. The uncertainty of the estimate was quantified by calculating an approximate 95% confidence (CI) interval for the peak in predicted future number of mesothelioma deaths and the year in which this peak was expected to occur. Our estimate of the predicted peak was scaled to include mesothelioma deaths in men aged 9 years or older, and deaths among women. Mesothelioma mortality is very low up to 2 years after first asbestos exposure even among heavily exposed workers (Peto et al, 1982), so death rates up to 21 give virtually no information on exposures in the previous 2 years. The level and timing of the predicted peak in mortality are virtually unaffected by exposure since 198, but for longer-term prediction recent exposures become increasingly relevant, and some assumption must be made about asbestos exposure since the 197s. An assessment of current exposure levels for a recent HSE Regulatory Impact Assessment (HSE, 22) suggested that population exposure in the 2 was around 4% of the peak value reached in the 196s. For the present projections, we assumed a continuing decline in asbestos exposure, from 4% of the peak level in 2 to 2% by 21 and.75% by 25. RESULTS The annual number of mesothelioma deaths in Great Britain has risen increasingly rapidly by about 12-fold from 1968 (the first year in which ascertainment is believed to be complete) to 21 (Figure 2). The mesothelioma death rate in males has continued to increase in older age groups, but has decreased among younger men in recent years (Figure 3). In 21, there were 1579 male deaths, 85% of the total, the majority being at ages 6 79 years, with relatively few aged less than 5 years. Less than 1% of deaths in men have occurred at age 9 or older, but the number is likely to increase substantially over time. Men born around 194 have suffered higher death rates than any previous or subsequent birth cohort (Figures 1A and B), and they will not reach 9 years of age until 23. Parameter values estimated from the two versions of the Poisson regression model are shown in the Table 1. The two versions of the model produced effectively equivalent fits overall, and showed very similar patterns of residuals. This is illustrated (for the nonclearance model) in Figures 4A C which show plots of fitted and observed deaths by year of birth, age and year of death. These show close agreement. A two-dimensional array (not shown) of deviance residuals by 5-year age and year of birth groupings also showed an unbiased pattern with no strong clustering of residuals of the same sign. While the fit of the clearance and nonclearance British Journal of Cancer (25) 92(3), 587 593

versions of the model to past data were equivalent, their predictions of future mortality were different. Under the nonclearance model, the annual number of mesothelioma deaths in men aged below 9 years is predicted to reach a peak of 1846 deaths (95% CI 165 21) in 213 (95% CI 211 215). The clearance model predicts a peak of 1983 deaths (95% CI 1835 2233) in 211 (95% CI 29 213). As more data accumulate on the pattern of reduced mortality related to exposure levels after the mid-196s peak, it may be possible to estimate the parameters k and H separately. Allowing for deaths occurring in men aged 9 or over, the estimated peak among males is 1857. Assuming a linear relationship between annual numbers of male M and female F mesothelioma deaths (F ¼ 22.9 þ.136m; R 2 ¼.95), the maximum number of female deaths was estimated to be 276, giving a predicted total of 2133 mesothelioma deaths (95% CI 195 245) at the peak of the epidemic. The total number of mesothelioma deaths to 25 is predicted to be around 9, with 65 of these occurring from 22 onwards. Rate per million 1. 1. 1. 1..1 197 72 1973 75 1976 78 1979 81 1982 84 1985 87 1988 9 1991 93 1994 96 1997 99 2 2p 3-Year time period 15 44 yr 45 54 yr 55 64 yr 65 74 yr 75+ yr Figure 3 Average annual male mesothelioma death rates per million by age and time period. 589 Figure 2 Table 1 2 18 16 14 12 1 8 6 4 2 1968 197 Mesothelioma deaths by sex and year. Males Females Total 1972 1974 1976 1978 198 1982 1984 Estimated parameter values from optimal Poisson s regression model Year 1986 1988 199 1992 1994 1996 1998 2 Parameter Estimates for non clearance model (half life ¼ 1 years) Estimates for model with clearance half life of 15 years Power of time since first exposure, k 2.6 4.1 Year of exposure maximum 1967 1962 Diagnostic trend (percentage decrease in missed cases per year), Dx T 5 2 Relative exposure potential for age group (years) 4.. 5 15.3.7 16 19.21 1.18 2 29 1. (baseline) 1. (baseline) 3 39 1.24 1.95 4 49 1.11 1.2 5 59..8 6 64.. 65+.. Change in exposure index (percentage per year) in peak year7x years % change % change 45 29 3 35 6 8 25 11 11 15 9 9 5 5 1 (peak year) +5 14 17 +15 39 4 British Journal of Cancer (25) 92(3), 587 593

59 A C Asbestos exposure index 1 1 1 1.1 2 18 16 14 12 1 8 6 4 2 1878 1883 1888 1893 1898 193 198 1913 Exposure index Fitted mesothelioma deaths Observed mesothelioma Fitted Observed 1918 1923 Year of birth 1928 1933 1938 1943 1948 1953 1958 1963 1968 1973 19 197 1914 1921 1928 1935 1942 1949 1956 1963 197 1977 1984 1991 1998 25 212 219 226 233 24 247 B 2 18 16 14 12 1 8 6 4 2 9 8 7 6 5 4 3 2 1 Fitted Observed 2 25 3 35 4 45 5 55 6 65 7 75 8 85 Age (years) Year Year of birth Figure 4 (A) Observed and fitted deaths by year of birth. (B) Observed and fitted deaths by age. (C) Observed and fitted mesothelioma deaths by year of death, with derived exposure index. (D) Number of observed and fitted mesothelioma deaths for 1955 198 yearly birth cohorts. D 16 14 12 1 8 6 4 2 1955 1958 1961 1964 1967 197 Observed Fitted 1973 1976 1979 DISCUSSION The age cohort model was fitted (residual deviance 121.5 on 72 degrees of freedom) and confirmed the observed departure of the data from that model by providing a significantly worse fit than our preferred model (residual deviance 235.6 on 182 degrees of freedom). The existence of two versions of the model (one with clearance and the other with no clearance) with equivalent overall fits but with different future implications raises the obvious question as to which is closest to the truth. One way of assessing which model is the most realistic is to match the implied exposure patterns from each of the models with the actual pattern of asbestos imports, taking account of the difference between fibre types. Figure 5A shows the fitted exposure index for the nonclearance model together with the best approximating linear combination of the three fibre-specific import profiles, and Figure 5B shows this information for the lung clearance model (chrysotile had zero weight in both). It is evident that overall approximation is less good for the clearance than for the nonclearance exposure index. Although this argument is not definitive, we interpret the better agreement of imports with the exposure profile associated with the nonclearance model as justifying a modest preference for this model in developing our current projections. This preference is reinforced by the fact that the observed 21 total number of mesothelioma deaths is a more extreme outlier in relation to the clearance model (1563 observed vs 1463 expected, P ¼.22) than in relation to the nonclearance model (1488 expected, P ¼.143). Our assumption that exposure in 2 was 4% of the peak level hardly affects the predicted peak in mesothelioma mortality. It does, however, influence the predicted number of cases following the peak. Thus, the total burden of mesothelioma mortality to 25 remains very uncertain. The estimated power of time since first exposure of 2.6 is in the range expected on the basis of fits of similar models to cohort data, providing a measure of support for the application of the model at that population level. The diagnostic trend, a decrease of 5% per year in the proportion of cases that are undiagnosed, implies that in 1968 about 9% of cases were diagnosed. This parameter improves the fit but has virtually no influence on the projections. The model was fitted by minimising the total deviance. Recent birth cohorts have fewer mesothelioma deaths, so the fitted model is dominated by earlier cohorts with longer follow-up. The 192 1924 cohort has the most deaths. Residuals for the most recent cohorts therefore provide an indicator of predictive reliability. Figures 4A and D show observed and fitted deaths by year of birth, with some divergence for the most recent births (Figure 4D). From 1965 onwards there are eight deaths compared to a fitted value of 3.5, a borderline significant excess (P ¼.54). However, the fitted model does not include an allowance for a background rate of mesothelioma. If there were, as widely assumed, around 1 2% of male mesothelioma deaths not due to asbestos exposure, this equates to around 5 male deaths annually in Great Britain. On this basis, around four deaths would be expected among those not exposed to asbestos and born from 1965 onwards, bringing observed and fitted into good agreement. As data accumulates in these more recently born groups, it will be important to make explicit allowance in the model for the possibility of a background rate. In terms of projecting the timing and level of peak mortality, however, the numbers generated by this background rate can be ignored. Predictions of the future number of mesothelioma cases have been attempted in other countries. For example, in Denmark, the British Journal of Cancer (25) 92(3), 587 593

A 2 18 591 16 14 12 1 B 8 6 4 2 192 1922 2 18 16 14 12 Imports amosite +.7 x crocidilite Nonclearance model derived exposure 1924 1926 1928 193 1932 1934 1936 1938 194 1942 1944 1946 Imports amosite + 2.2 crocidilite Clearance model derived exposure index 1948 195 Year 1952 1954 1956 1958 196 1962 1964 1966 1968 197 1972 1974 1976 1978 1 8 6 4 2 192 1923 1926 1929 1932 1935 1938 1941 1944 1947 195 1912 cases of malignant mesothelioma reported to the Danish cancer registry between 1943 and 1993 were used to predict a peak incidence of 93 cases among men born before 1955 to around the year 215 (Kjaergaard, 2). In the United States, using mesothelioma incidence data from the Surveillance, and End Results programme, it has been estimated that there will be a peak around the years 2 to 24 of approximately 2 cases and a return to background incidence by 255 (Price and Ware, 24). In Australia, the incidence of mesothelioma is expected to peak around 7 cases per year in 21 (Leigh and Driscoll, 23). In Sweden, the preventive measures of the mid-197s can probably not be evaluated with reasonable precision until around 25 (Jarvholm et al, 1999). In the Netherlands, it has been predicted that pleural mesothelioma will peak around the year 228, with up to 9 cases per year (Segura et al, 23). In France, the number of deaths is predicted to reach a peak at about 22 per year some time after 22 (Ilg et al, 1998). Based on combined data from Britain, France, Germany, Italy, the Netherlands, Switzerland and Hungary, it has been suggested that the number of men dying Year from mesothelioma will almost double over the next 2 years, peaking at about 9 cases around 218 (Peto et al, 1999). These projections like the earlier British projections (Peto et al, 1995) were based on a simple age and birth cohort model. More recent death rates in three of these countries (France, Germany and Italy) are lower than were predicted, and the timing and level of the peak of Europe-wide mesothelioma deaths may prove to be earlier and lower, respectively, than previous projections suggested. CONCLUSIONS 1953 1956 1959 1962 1965 1968 1971 1974 1977 Figure 5 (A) Fitted import index for nonclearance model with best approximating weighting of actual import series (amosite þ.7 crocidolite. (B) Fitted import index for clearance model with best approximating weighting of actual import series (amosite þ 2.2 crocidolite). The data for 21 showed around 185 mesothelioma deaths among males and females in Great Britain. Using a statistical modelling approach, mesothelioma mortality in Great Britain is predicted to peak at around 195 245 deaths per year some time between 211 and 215. Around 9 deaths are predicted to occur by 25, with 65 of these occurring from 22 onwards. British Journal of Cancer (25) 92(3), 587 593

592 ACKNOWLEDGEMENTS We would like to thank Tracy Hamilton, Karen Hughes and Lori Woods for the maintenance and associated administration of the mesothelioma register. In addition we would like to thank the staff at the Office for National Statistics and the General Register Office for Scotland for mesothelioma mortality data staff at the Information and Statistics Division of the Scottish Health Service, the Office for National Statistics and the Welsh Cancer Registry for cancer registration data, staff at the National Health Service Central Registers in Southport and Edinburgh for death information for flagged cancer registrations. REFERENCES Berry G (1991) Prediction of mesothelioma, lung cancer, and asbestosis in former Wittenoom asbestos workers. Br J Ind Med 48: 793 82 Bianchi C, Giarelli L, Grandi G, Brollo A, Ramani L, Zuch C (1997) Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prev 6: 162 166 Doll R, Peto J (1985) Effects on Health of Exposure to Asbestos. London:HMSO Greenberg M, Lloyd Davies TA (1974) Mesothelioma register 1967 68. Br J Ind Med 31: 91 14 Health Effects Institute (1991) Asbestos in Public and Commercial Buildings: A Literature Review and Synthesis of Current Knowledge. Cambridge, MA: Health Effects Institute Asbestos Research Hodgson JT, Peto J, Jones R, Matthews FE (1997) Mesothelioma mortality in britain: patterns by birth cohort and occupation. Ann Occup Hyg 41(Suppl 1): 129 133 HSE (22) Amendment to the Control of Asbestos at Work Regulations 1987 and ACoP: Regulatory Impact Assessment (available on the web at http:// www.hse.gov.uk/ria/chemical/ria-176.pdf). Health and Safety Executive Ilg AG, Bignon J, Valleron AJ (1998) Estimation of the past and future burden of mortality from mesothelioma in France. Occup Environ Med 55: 76 765 Jarvholm B, Englund A, Albin M (1999) Pleural mesothelioma in Sweden: an analysis of the incidence according to the use of asbestos. Occup Environ Med 56: 11 113 Kjaergaard J, Andersson M (2) Incidence rates of malignant mesothelioma in Denmark and predicted future number of cases among men. Scand J Work Environ Health 26: 112 117 Leigh J, Driscoll T (23) Malignant mesothelioma in Australia, 1945 22. Int J Occup Environ Health 9: 26 217 McElvenny DM, Darnton AJ, Price MJ, Hodgson IT (25) Mesothelioma mortality in Great Britain from 1968 21. (In press) Peto J (1979) Dose response relationships for asbestos-related disease: implications for hygiene standards. Part II. Mortality. Ann NY Acad Sci 33: 195 23 Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer 79: 666 672 Peto J, Matthews FE, Hodgson JT, Jones JR (1995) Continuing increase in mesothelioma mortality in Britain. Lancet 345: 535 539 Peto J, Seidman H, Selikoff IJ (1982) Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer 45: 124 135 Price B, Ware A (24) Mesothelioma trends in the United States: an update based on Surveillance,, and End Results Program data for 1973 through 23. Am J Epidemiol 159: 17 112 Segura O, Burdorf A, Looman C (23) Update of predictions of mortality from pleural mesothelioma in the Netherlands. Occup Environ Med 6: 5 55 Appendix A1 THE POISSON REGRESSION MODEL Introduction Mesothelioma mortality rises rapidly with increasing time since first asbestos exposure but is independent of age (Peto et al, 1982). These observations can be explained by a dose response model in which the increase in subsequent mesothelioma risk caused by each episode of asbestos exposure is proportional to the cumulative dose inhaled and to the second or third power of time since the exposure (Peto, 1979). The fit is slightly improved up to 2 years after first exposure by assuming a lag of 1 years before mortality begins to increase (Peto et al, 1982). This relationship has been used as a basis for risk assessment and regulation by several agencies, including the United Kingdom (Doll and Peto, 1985) and the United States of America (Health Effects Institute, 1991). We have adapted the model to find an asbestos exposure distribution by year and by age that generates predicted mesothelioma deaths by year and age close to the observed pattern from 1968 to 21, and hence to predict future rates. The model was developed to predict an individual s risk from his level of asbestos exposure in each previous year, but we have used it to predict the death rate in each birth cohort of British men as a function of their average exposure in each year. Model formulation Under the dose response model for mesothelioma developed by the Health Effects Institute (HEI) (Health Effects Institute, 1991), an individual s additional mesothelioma risk caused by each brief exposure to asbestos is proportional to the increase in cumulative exposure D multiplied by the second or third power of time t since the exposure lagged by 1 years: R / Dðt 1Þ k As the predicted risk after a given interval is directly proportional to the exposure D, the HEI model can also be applied at the population level to death rates in each birth cohort, replacing an individual s asbestos exposure D in a given period by the corresponding average collective dose. The following additional assumptions were incorporated in the model we have fitted: (i) Average asbestos exposure to the male population of Great Britain in each year is summarised by a single estimate, but exposure also varies with age. This age dependence for exposure is assumed to be the same in all past and future periods. (ii) A trend in the completeness of mesothelioma diagnosis over time is included. (iii) A half-life of 1 years was arbitrarily assumed for the proportion of fibres remaining in the lung. (The shorter halflife of 15 years increased the estimated power k but gave similar goodness of fit and predictions.) The mesothelioma death rate for men aged A in year T was approximated by the sum of the risks due to exposure in all previous years of their lifetime, excluding the most recent 1 years. For each of these individual years, the contribution to the predicted death rate was calculated as the product of the appropriate age-specific exposure factor, the overall population exposure index for that year and the lagged time interval to year T raised to the power k. The predicted number of mesothelioma deaths at age A in year T is then proportional to the sum of these risk contributions multiplied by the estimated proportion of mesothelioma cases in year T that were diagnosed, and the total population aged A in year T (i.e. the person-years for age A and year T). Rescaling so that the total fitted number of mesothelioma British Journal of Cancer (25) 92(3), 587 593

deaths in the period 1968 21 is equal to the total observed number in the same period gives the predicted number of deaths for persons aged A in year T. The model can be represented mathematically as follows: hp i A 1 f g k :5 1=H Dx T P A;T M F A;T ¼ P A;T l¼ W A ld T l l þ 1 L hp A 1 l¼ W A ld T l fl þ 1 Lg k :5 1=H i Dx T P A;T where F A,T is the number of deaths at age A in year T; W A is the age-specific exposure potential at age A; D T is the overall population exposure in year T; Dx T is the proportion of mesothelioma deaths in year T that are recorded; L is the lag period in years between exposure and disease occurrence; H is the half-life in years for asbestos clearance from the lungs; k is the exponent of time representing the increase of risk with increase of time since exposure; P A,T is the person-years at risk for age A in year T; M is the total observed mesothelioma deaths 1968 21; the content of {} is set to zero when negative; the summations indexed by l represent the cumulative effect at age A of the exposures at earlier ages; and l indexes years lagged from the risk year. Details of model parameters Age-specific exposure potential W A was defined by assigning nine parameters to the age groups 4, 5 15, 16 19, 2 29, 3 39, 4 49, 5 59, 6 64 and 65 þ years. Age group 2 29 years was chosen as the baseline category. General exposure level in a given year D T is the average effective carcinogenic dose in the breathing zone of men aged 2 29 years. If crocidolite were (for example) five times more dangerous than amosite, its contribution to D T per unit dose would be five times greater. The exposure distribution was defined by growth and decline rates for years in multiples of 1 before and after the maximum exposure year (in which exposure growth/decline is zero). Growth rates for years intermediate between the 1-yearly values were determined by linear interpolation. Owing to the long latency of mesothelioma, exposures after 198 could not be estimated. Based on an assessment of the current distribution of exposures (set out in detail in a recent HSE Regulatory Impact Assessment HSE, 22), it was assumed that the total asbestos exposure to the population in 2 would be approximately 4% of the peak value. Using predicted building demolition rates from 21 to 25, it was estimated that exposure would be at 2% of the maximum by 21 and.75% of the maximum by 25. Diagnosis was assumed to be essentially complete (98%) in 1997. The diagnostic trend Dx T was parameterised as the annual percentage increase in the number of missed cases working backwards in time from this year. Clearance of fibres from the lung was assumed to follow an exponential decline parameterised by its half-life H. Testing of model adequacy and uncertainty The adequacy of the final model was assessed by examining deviance residuals and comparing plots of observed and expected mesothelioma deaths. Approximate 95% CIs for the level and the timing of the predicted peak in mesothelioma deaths were calculated by adjusting model parameters to produce a lower/earlier peak and a higher/later peak, corresponding to a change in the deviance from the optimal model equivalent to the 5% critical value of the w 2 distribution on the number of degrees of freedom in the model. The resultant ranges are roughly equivalent to 95% CIs, but are slightly narrower, since they cannot take account of uncertainties in the mathematical formulation of the model. 593 British Journal of Cancer (25) 92(3), 587 593